Gallbladder CancerNCT02692911
Chile Biliary Longitudinal Study
An observational study of Gallbladder Cancer and Nutritional and Metabolic Diseases, run by National Cancer Institute (NCI) at 3 sites in Chile.
Trial summary
Background: The gallbladder is a small organ below the liver. Gallbladder cancer is a leading cause of cancer death among women in Chile. Chile also has among the highest rates of gallbladder cancer and death in the world. Researchers in a high-risk region of Chile want to find out more about this type of cancer. Read more about this study
- Who is it for?
- Ages 50 to 74 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Gallbladder Cancer, Nutritional and Metabolic Diseases
- How many people
- 4,749 participants
- Where
- 3 sitesChile
- Study dates
- 11 Jan 2017to 15 Jun 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 74 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subject identification will begin with a census of the target neighborhoods in Chile in the study areas. Potential participants will be contacted by study staff (healthcare assistants), who will conduct home visits. If participant is eligible, study staff will invite the individual to participate and obtain written informed consent. She will then schedule an appointment at the study center for the screening ultrasound and give her the instructions to prepare for the examination.
Who may be able to join
- General Population Cohort:
- Female
- Age 50 years to 74 years
- No previous cholecystectomy
- Covered by National Health Insurance
- Resident of Araucania (or Maule)
Show all 18Show fewer
- Able to answer questionnaire (due to language/communication issues or mental incapacity)
- Other control (general population or cholecystectomy):
- No previous cholecystectomy
- Covered by National Health Insurance
- Resident of Araucania (or Maule)
- Able to answer questionnaire (due to language/communication issues or mental incapacity)
- Gallbladder Cancer Group:
- Diagnosis within study time period
- Primary site of cancer is the gallbladder with histological or radiological confirmation
- Covered by National Health Insurance
- Resident of Araucania (or Maule)
- Able to answer questionnaire (due to language/communication issues or mental incapacity)
Who cannot join
- General Population Cohort:
- Male
- Age less than 50 years or greater than 74 years
- History of previous cholecystectomy
- Not covered by National Health Insurance
- Not a Resident of Araucania (or Maule)
Show all 18Show fewer
- Unable to answer questionnaire (due to language/communication issues or mental incapacity)
- Other control (general population or cholecystectomy):
- History of previous cholecystectomy
- Not covered by National Health Insurance
- Not a Resident of Araucania (or Maule)
- Unable to answer questionnaire (due to language/communication issues or mental incapacity)
- Gallbladder Cancer Group:
- Diagnosis not within study time period
- Primary site of cancer is NOT the gallbladder with histological or radiological confirmation
- Not covered by National Health Insurance
- Not a Resident of Araucania (or Maule)
- Unable to answer questionnaire (due to language/communication issues or mental incapacity)
Trial locations and contacts
3 sites in 1 country.
Chile3 sites
Hospital Regional de Talca
Talca
Universidad Catolica del Maule
Talca
Hospital Regional de Temuco
Temuco
About this study
Background:
The gallbladder is a small organ below the liver. Gallbladder cancer is a leading cause of cancer death among women in Chile. Chile also has among the highest rates of gallbladder cancer and death in the world. Researchers in a high-risk region of Chile want to find out more about this type of cancer. They especially want to know how inflammation affects the way it develops.
Read more
Objective:
To better understand the causes of gallbladder diseases and factors that may be associated with them.
Eligibility:
Women ages 50 74 with gallbladder cancer who are covered by the Chilean national health system.
Other people over age 21 with gallbladder disease.
Healthy adults over age 21.
Design:
Participants may be screened with an ultrasound. They may be asked questions about their health.
Participants will have an ultrasound of the abdomen. This can be done at the study clinic or in the hospital or at home. The ultrasound uses sound waves to take pictures of the gallbladder.
Participants will have a physical exam.
Participants will have their mouths looked at for tooth loss, dentures, and gum redness.
Participants will give a blood sample or saliva sample.
Participants will be asked for access to their medical history. They may be asked to allow researchers to keep any samples taken during gallbladder surgery.
Participants will answer questions about their medical history. This will include illnesses, surgeries, medicine use, and family history. It will also include diet and lifestyle habits, such as places where they have lived and worked.
Some participants will have 3 follow-up visits over 6 years.
...
Read the detailed description
Gallbladder cancer is a leading cause of cancer death among women in Chile, which has among the highest reported gallbladder cancer incidence and mortality rates in the world. Gallbladder cancer provides a particularly good model for understanding the role of inflammation in carcinogenesis since the major risk factor, gallstones, causes substantial inflammation in the gallbladder. Chile also has a high prevalence of obesity, diabetes, and metabolic syndrome, which are increasingly understood as inflammatory disorders, but the extent to which their carcinogenic effects are mediated through inflammatory pathways is unknown.
While the vast majority of gallbladder cancer cases have gallstones, only a small fraction of gallstone patients ever develop gallbladder cancer. Since there is no way to identify this small proportion at risk, gallstone cases are cholecystectomized, which, given large absolute numbers of individuals with gallstones, results in overtreatment of some and under-treatment of others in a high-risk area like Chile. While cholecystectomy is standard treatment for symptomatic relief, there are more people who need surgery than there are surgeons to perform them, and individuals aged 34-49 are prioritized for treatment, regardless of symptoms. This practice may lead to overtreatment among 34-49-year-olds and under treatment of individuals aged 50 and above since they have to wait longer for surgery. At the same time, about 30% of patients with a biliary colic attack will never have another attack, and cholecystectomy does not always lead to the cessation of symptoms. In addition, cholecystectomy has been associated with an increased risk of other digestive diseases. Thus, cholecystectomy may not be needed in all gallstone patients and may in fact increase the risk of cancer in some. Better predictors of risk are clearly needed.
As with other cancers, dysplasia is an important epidemiologic endpoint as the immediate precursor to cancer since the vast majority of gallbladder cancers develop through a histologic continuum of chronic cholecystitis, pseudopyloric metaplasia, incomplete intestinal metaplasia, dysplasia, and cancer. Thus, our aim is to identify risk factors for gallbladder dysplasia and cancer (GDC) and potential non-invasive risk stratification methods, such as ultrasound characteristics alone or in combination with inflammatory markers and patient characteristics, to better understand the etiology and natural history of GDC and to help inform strategies for GDC prevention.
Together with collaborators at Pontifica Universidad Catolica (PUC), we successfully completed a pilot study in Chile that was previously reviewed and approved by SAG and provided baseline data for the proposed study. Our pilot demonstrated high recruitment rates in the target enrollment area (80%) and high rates of questionnaire completion (100%), blood collection (78% population-based controls), and participant retention (93% of eligible completed a follow-up visit). Information from the pilot was used to optimize procedures for the longitudinal study. We also found that both gallstones and gallbladder cancer were associated with systemic immune alterations, which as we previously demonstrated, reflect inflammatory changes in the gallbladder detectable in bile. The next step is to demonstrate that these markers precede GDC by longitudinally measuring their levels among gallstone patients.
We propose to prospectively assess risk factors and early detection markers for GDC by conducting the Chile Biliary Longitudinal Study (BiLS), a cohort study of 6250 individuals with gallstones from the high- risk southern-central region of Chile. Because women are twice as likely to have gallstones and twice as likely to have gallbladder cancer as men, we plan to maximize our screening efficiency and number of outcomes by screening and enrolling women only. This approach is reasonable given that the female gender bias for gallbladder cancer is largely thought to be due to the gender bias for gallstones,1-3 suggesting that in the presence of gallstones, the risk of gallbladder cancer is the same for men and women. In addition, Chile is conducting a general population cohort in a small town in the high-risk area, and we can use the men with gallstones enrolled by the Chilean study to compare to the women in our study. We plan to enroll women with gallstones over 2 years and follow them for 6 years, conducting visits every other year to collect data on the primary exposures of interest, inflammatory markers and ultrasound characteristics, as well as additional exposures of interest, such as infections, genetics, and environmental exposures (e.g., aflatoxin, pesticides).
- Keywords
- Gallbaldder, Cancer, Gallstones, Cholecystectomy, Inflammation
- Medical subject headings
- Gallbladder Neoplasms, Nutritional and Metabolic Diseases, Neoplasms, Gallstones, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Women with gallstones | Women aged 50-74 with gallstones |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cancer/precancer
Our major exposures of interest are patterns, levels, and changes in inflammatory markers and ultrasound characteristics, with Gallbladder Dysplasia and Cancer as the primary outcome of interest.
Measured: during course of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Feb 2016 (estimated)
- Study start11 Jan 2017
- Primary completion15 Jun 2020
- Study completion15 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gallbladder CancerStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 4,749 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Jill E. Koshiol, M.D., Principal investigator, National Cancer Institute (NCI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02692911
- Sponsor's protocol ID
- 999916070
- Other IDs
- 16-C-N070
- Status last verified
- Jun 2020
- First submitted
- 25 Feb 2016
- Last updated
- 12 Mar 2021
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chile Biliary Longitudinal Study
- ClinicalTrials.gov ID
- NCT02692911
- Acronym / sponsor ID
- 999916070
- Keywords
- Gallbaldder, Cancer, Gallstones, Cholecystectomy, Inflammation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,749 participants (estimated)
- Lead sponsor
- National Cancer Institute (NCI)US National Institutes of Health
- Study start
- 11 Jan 2017 (actual)
- Primary completion
- 15 Jun 2020 (actual)
- Study completion
- 15 Jun 2020 (actual)
- First posted
- 26 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
The gallbladder is a small organ below the liver. Gallbladder cancer is a leading cause of cancer death among women in Chile. Chile also has among the highest rates of gallbladder cancer and death in the world. Researchers in a high-risk region of Chile want to find out more about this type of cancer. They especially want to know how inflammation affects the way it develops.
Objective:
To better understand the causes of gallbladder diseases and factors that may be associated with them.
Eligibility:
Women ages 50 74 with gallbladder cancer who are covered by the Chilean national health system.
Other people over age 21 with gallbladder disease.
Healthy adults over age 21.
Design:
Participants may be screened with an ultrasound. They may be asked questions about their health.
Participants will have an ultrasound of the abdomen. This can be done at the study clinic or in the hospital or at home. The ultrasound uses sound waves to take pictures of the gallbladder.
Participants will have a physical exam.
Participants will have their mouths looked at for tooth loss, dentures, and gum redness.
Participants will give a blood sample or saliva sample.
Participants will be asked for access to their medical history. They may be asked to allow researchers to keep any samples taken during gallbladder surgery.
Participants will answer questions about their medical history. This will include illnesses, surgeries, medicine use, and family history. It will also include diet and lifestyle habits, such as places where they have lived and worked.
Some participants will have 3 follow-up visits over 6 years.
...
Detailed description
Gallbladder cancer is a leading cause of cancer death among women in Chile, which has among the highest reported gallbladder cancer incidence and mortality rates in the world. Gallbladder cancer provides a particularly good model for understanding the role of inflammation in carcinogenesis since the major risk factor, gallstones, causes substantial inflammation in the gallbladder. Chile also has a high prevalence of obesity, diabetes, and metabolic syndrome, which are increasingly understood as inflammatory disorders, but the extent to which their carcinogenic effects are mediated through inflammatory pathways is unknown.
While the vast majority of gallbladder cancer cases have gallstones, only a small fraction of gallstone patients ever develop gallbladder cancer. Since there is no way to identify this small proportion at risk, gallstone cases are cholecystectomized, which, given large absolute numbers of individuals with gallstones, results in overtreatment of some and under-treatment of others in a high-risk area like Chile. While cholecystectomy is standard treatment for symptomatic relief, there are more people who need surgery than there are surgeons to perform them, and individuals aged 34-49 are prioritized for treatment, regardless of symptoms. This practice may lead to overtreatment among 34-49-year-olds and under treatment of individuals aged 50 and above since they have to wait longer for surgery. At the same time, about 30% of patients with a biliary colic attack will never have another attack, and cholecystectomy does not always lead to the cessation of symptoms. In addition, cholecystectomy has been associated with an increased risk of other digestive diseases. Thus, cholecystectomy may not be needed in all gallstone patients and may in fact increase the risk of cancer in some. Better predictors of risk are clearly needed.
As with other cancers, dysplasia is an important epidemiologic endpoint as the immediate precursor to cancer since the vast majority of gallbladder cancers develop through a histologic continuum of chronic cholecystitis, pseudopyloric metaplasia, incomplete intestinal metaplasia, dysplasia, and cancer. Thus, our aim is to identify risk factors for gallbladder dysplasia and cancer (GDC) and potential non-invasive risk stratification methods, such as ultrasound characteristics alone or in combination with inflammatory markers and patient characteristics, to better understand the etiology and natural history of GDC and to help inform strategies for GDC prevention.
Together with collaborators at Pontifica Universidad Catolica (PUC), we successfully completed a pilot study in Chile that was previously reviewed and approved by SAG and provided baseline data for the proposed study. Our pilot demonstrated high recruitment rates in the target enrollment area (80%) and high rates of questionnaire completion (100%), blood collection (78% population-based controls), and participant retention (93% of eligible completed a follow-up visit). Information from the pilot was used to optimize procedures for the longitudinal study. We also found that both gallstones and gallbladder cancer were associated with systemic immune alterations, which as we previously demonstrated, reflect inflammatory changes in the gallbladder detectable in bile. The next step is to demonstrate that these markers precede GDC by longitudinally measuring their levels among gallstone patients.
We propose to prospectively assess risk factors and early detection markers for GDC by conducting the Chile Biliary Longitudinal Study (BiLS), a cohort study of 6250 individuals with gallstones from the high- risk southern-central region of Chile. Because women are twice as likely to have gallstones and twice as likely to have gallbladder cancer as men, we plan to maximize our screening efficiency and number of outcomes by screening and enrolling women only. This approach is reasonable given that the female gender bias for gallbladder cancer is largely thought to be due to the gender bias for gallstones,1-3 suggesting that in the presence of gallstones, the risk of gallbladder cancer is the same for men and women. In addition, Chile is conducting a general population cohort in a small town in the high-risk area, and we can use the men with gallstones enrolled by the Chilean study to compare to the women in our study. We plan to enroll women with gallstones over 2 years and follow them for 6 years, conducting visits every other year to collect data on the primary exposures of interest, inflammatory markers and ultrasound characteristics, as well as additional exposures of interest, such as infections, genetics, and environmental exposures (e.g., aflatoxin, pesticides).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Women with gallstones | – | –Women aged 50-74 with gallstones |
Who may qualify
- Ages
- 50 to 74 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subject identification will begin with a census of the target neighborhoods in Chile in the study areas. Potential participants will be contacted by study staff (healthcare assistants), who will conduct home visits. If participant is eligible, study staff will invite the individual to participate and obtain written informed consent. She will then schedule an appointment at the study center for the screening ultrasound and give her the instructions to prepare for the examination.
Key inclusion criteria (18 listed)
- Female
- Age 50 years to 74 years
- No previous cholecystectomy
- Covered by National Health Insurance
- Resident of Araucania (or Maule)
Key exclusion criteria (18 listed)
- Male
- Age less than 50 years or greater than 74 years
- History of previous cholecystectomy
- Not covered by National Health Insurance
- Not a Resident of Araucania (or Maule)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cancer/precancer
Time frame: during course of the study
Our major exposures of interest are patterns, levels, and changes in inflammatory markers and ultrasound characteristics, with Gallbladder Dysplasia and Cancer as the primary outcome of interest.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2021.
Related trials for Gallbladder Cancer
RecruitingObservational study
Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag Locality
Gall Bladder Carcinoma
Active, not recruitingPhase 2/3
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8
Active, not recruitingPhase 2
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Active, not recruitingPhase 3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Biliary Tract Cancer
RecruitingPhase 1/2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Biliary Tract Cancer, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jill E. Koshiol, M.D. principal investigator
National Cancer Institute (NCI)
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gallbladder Cancer and Nutritional and Metabolic Diseases, run by National Cancer Institute (NCI) at 3 sites in Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cancer/precancer (time frame: during course of the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2021; AzTrials last refreshed its copy on 26 Oct 2026.